Pentec Health

Pentec Health operates three core lines: clinical nutrition (including IDPN/IPN, parenteral and enteral nutrition, medical foods, and low-protein products), intrathecal home infusion for chronic pain and muscle spasticity management, and hepatic artery home infusion for liver-directed cancer therapy. Each service combines sterile compounding, durable infusion-pump management, in-home nursing coordination, and clinician education, enabling hospitals and outpatient specialists to discharge complex patients to the community.

Pentec covers chronic kidney disease, end-stage renal disease, chronic non-healing wounds, short bowel syndrome, exocrine pancreatic insufficiency, cystic fibrosis, and a suite of rare metabolic conditions: phenylketonuria (PKU), homocystinuria (HCU), maple syrup urine disease (MSUD), tyrosinemia type 1, propionic acidemia, methylmalonic acidemia, glutaric acidemia type 1, and urea cycle disorders. It also manages chronic pain, muscle spasticity, and cancer metastatic to the liver.

No ownership structure is disclosed in any public source. The company publishes no financial filings, investor-relations pages, or sponsor announcements, and its website makes no mention of external shareholders. Without a LinkedIn corporate page or press-release history beyond its own newsroom, a definitive ownership attribution is not possible from open material.

Pentec Health carries Joint Commission national quality approval and the American Nurses Credentialing Center’s Practice Transition Program with Distinction. It is also listed as a provider member of the National Home Infusion Association, signaling conformance to industry quality and safety standards for sterile compounding and home-infusion nursing.

No evidence of a venture arm, fund entity, or family-office structure exists in any public source. The firm’s entire public-facing presence describes operational healthcare delivery. If such a structure exists, it is offline and has not been referenced in accessible publications or filings.